Regeneron Pharmaceuticals Inc (REGN)
$635.66+2.50%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Dupixent growth offsets Eylea biosimilar risk; recent price drop offers compelling entry into high-quality biotech.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and …
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- $63.9B
Recent dividends
- 20 May 2026$0.94
- 20 Feb 2026$0.94
- 20 Nov 2025$0.88
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Regeneron Pharmaceuticals Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free